Atazanavir plus raltegravir 300/400 mg twice daily is being explored as a ritonavir- and nucleoside- sparing treatment strategy. The pharmaco-kinetics and safety of this combination in healthy individuals were evaluated.
Methods
A total of 22 healthy individuals received raltegravir 400 mg on days 1–5, atazanavir 300 mg on days 6–12 and atazanavir plus raltegravir 300/400 mg on days 13–26, twice daily with a light meal. Serial blood samples were collected 12 h after the morning dose on days 5, 12 and 26; safety assessments, clinical laboratory data and serial electrocardiograms (ECGs) at 0, 2 and 6 h were obtained.
Results
Raltegravir coadministration reduced atazanavir geometric mean maximum plasma concentration (Cmax), area under the plasma concentration–time curve from 0 to 12 h post-dose (AUC0–12) and trough plasma concentration (Cmin) by 11%, 17% and 29%, respectively, compared with atazanavir alone. Geometric mean atazanavir Cmin was 817 ng/ml (range 250–1,550) with raltegravir coadministration. Atazanavir increased raltegravir geometric mean Cmax, AUC0–12 and Cmin by 39%, 54% and 48%, respectively. All adverse events were of mild or moderate intensity. Hyperbilirubinaemia and ECG PR increases with atazanavir were similar to those of atazanavir/ritonavir once daily. No corrected QT prolongations were noted. Mean QRS increase from baseline was 11.0 ms (range 2–25) after receiving atazanavir for 7 days; no further QRS increase was noted and no QRS interval was >120 ms with raltegravir coadministration. No ECG changes were observed with raltegravir alone.
Conclusions
Coadministration of atazanavir and raltegravir 300/400 mg twice daily decreased atazanavir AUC0–12 and Cmin relative to atazanavir alone, and increased AUC0–12 of raltegravir relative to raltegravir alone. Atazanavir and raltegravir alone and coadministered appeared safe and well-tolerated.
References
1.
Reyataz (atazanavir).US prescribing information2009. Bristol–Myers SquibbPrinceton, NJ, USA.
2.
MalanD.R., KrantzE., DavidN., WirtzV., HammondJ., McGrathD.Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.J Acquir Immune Defic Syndr2008; 47: 161–167.
3.
MolinaJ.M., Andrade-VillanuevaJ., EchevarriaJ.Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.Lancet2008; 372: 646–655.
4.
CahnP.E., GatellJ.M., SquiresK.Atazanavir – a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.J Int Assoc Physicians AIDS Care (Chic Ill)2004; 3: 92–98.
Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Updated 1 December 2009. Accessed 4 December 2009.) Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
8.
CarrA.Treatment strategies for HIV lipodystrophy.Curr Opin HIV AIDS2007; 2: 332–338.
9.
KarrasA., LafaurieM., FurcoA.Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus.Clin Infect Dis2003; 36: 1070–1073.
10.
ZimmermannA.E., PizzoferratoT., BedfordJ., MorrisA., HoffmanR., BradenG.Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions.Clin Infect Dis2006; 42: 283–290.
11.
CazanaveC., DuponM., Lavignolle-AurillacV.Reduced bone mineral density in HIV-infected patients: prevalence and associated factors.AIDS2008; 22: 395–402.
12.
FoisyM.M., YakiwchukE.M., HughesC.A.Induction effects of ritonavir: implications for drug interactions.Ann Pharmacother2008; 42: 1048–1059.
GrinsztejnB., NguyenB.Y., KatlamaC.Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a Phase II randomised controlled trial.Lancet2007; 369: 1261–1269.
15.
ZhuL., MahnkeL., PerssonA.Pharmacokinetics, safety and tolerability of atazanavir 200, 300, and 400 mg in healthy subjects.48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Infectious Diseases Society of America Meeting. 25–28 October 2008, Washington, DC, USA.
16.
ZhangD., ChandoT.J., EverettD.W., PattenC.J., DehalS.S., HumphreysW.G.In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation.Drug Metab Dispos2005; 33: 1729–1739.
17.
KassahunK., McIntoshI., CuiD.Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme.Drug Metab Dispos2007; 35: 1657–1663.
18.
IwamotoM., WenningL.A., MistryG.C.Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.Clin Infect Dis2008; 47: 137–140.
19.
IwamotoM., KostJ.T., MistryG.C.Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval.J Clin Pharmacol2008; 48: 726–733.
MerschmanS.A., VallanoP.T., WenningL.A., MatuszewskiB.K., WoolfE.J.Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC–MS/MS.J Chromatogr B Analyt Technol Biomed Life Sci2007; 857: 15–24.
22.
SchusterA., BurzawaS., JemalM., LoizillonE., CouerbeP., WhiganD.Quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human plasma by liquid chromatography-tandem mass spectrometry following automated solid-phase extraction.J Chromatogr B Analyt Technol Biomed Life Sci2003; 788: 377–386.
23.
US Food and Drug Administration.Guidance for industry: drug interaction studies – study design, data analysis, and implications for dosing and labeling.Silver Spring, MD: US Food and Drug Administration2006.
24.
DickinsonL., KhooS., BackD.Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons.Curr Opin HIV AIDS2008; 3: 296–305.
25.
LaineL.Acid secretion in human immunodeficiency virus infection.Gastroenterology1993; 105: 298–299.
26.
Lake-BakaarG., ElsakrM., HagagN.Changes in parietal cell structure and function in HIV disease.Dig Dis Sci1996; 41: 1398–1408.
27.
WelageL.S., CarverP.L., RevankarS., PiersonC., KauffmanC.A.Alterations in gastric acidity in patients infected with human immunodeficiency virus.Clin Infect Dis1995; 21: 1431–1438.
